{"id":"ticagrelor-orodispersible-tablets","safety":{"commonSideEffects":[{"rate":"4-6","effect":"Bleeding (major and minor)"},{"rate":"13-14","effect":"Dyspnea (shortness of breath)"},{"rate":"3-5","effect":"Bradycardia"},{"rate":"2-3","effect":"Ventricular pauses"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelet surfaces, blocking platelet activation and aggregation. This antiplatelet effect reduces the risk of stent thrombosis and cardiovascular events in acute coronary syndrome and other thrombotic conditions. The orodispersible tablet formulation allows rapid dissolution in the oral cavity for faster onset of action compared to standard tablets.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:43.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events"},{"name":"Secondary prevention of atherothrombotic events in patients with prior myocardial infarction"}]},"trialDetails":[{"nctId":"NCT03869268","phase":"PHASE4","title":"The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2019-04-24","conditions":"Acute Coronary Syndrome","enrollment":72},{"nctId":"NCT03822377","phase":"PHASE3","title":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria di Sassari","startDate":"2019-06-27","conditions":"ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI","enrollment":130},{"nctId":"NCT02436577","phase":"PHASE1","title":"Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06","conditions":"Bioequivalence, Healthy Japanese Subjects, Pharmacokinetics","enrollment":51},{"nctId":"NCT02400333","phase":"PHASE1","title":"Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06","conditions":"Bioavailability, Healthy Subjects","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ticagrelor orodispersible tablets","genericName":"Ticagrelor orodispersible tablets","companyName":"Azienda Ospedaliero Universitaria di Sassari","companyId":"azienda-ospedaliero-universitaria-di-sassari","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}